The James Cancer Hospital is a leader is helping cancer patients deal with the pain that can be associated with treatment. “Our inpatient oncology rehabilitation service is the first in Ohio, the seco
Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.
The FDA released a draft guidance document detailing their interpretation of when a confirmatory clinical trial for an accelerated approval is underway.
Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.
Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.
The OSUCCC – James announces today it will form a new partnership with Zangmeister Cancer Center, a partner practice of American Oncology Network. This
Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma
The selection and schedule of treatment should depend on patient preference and toxicity potential, according to Azka Ali, MD.
Evan Y. Yu, MD, discusses how community oncologists can critically weigh the evidence from studies on androgen deprivation therapy plus androgen receptor pathway inhibitors regimens…
Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell therapy and ongoing efforts to expand its application beyond B-cell malignancies.
Nivolumab plus ipilimumab–based treatment regimens have shown long-term, durable efficacy benefits in patients with metastatic NSCLC. Here we report clinical outcomes from a pooled analysis…
